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Poxviruses  encode  a repertoire  of  immunomodulatory  proteins  to thwart  the host  immune  system.  One
among  this  array  is a homolog  of the  host  complement  regulatory  proteins  that  is conserved  in  vari-
ous  poxviruses  including  vaccinia  (VACV)  and variola.  The  vaccinia  virus  complement  control  protein
(VCP),  which  inhibits  complement  by  decaying  the  classical  pathway  C3-convertase  (decay-accelerating
activity),  and  by  supporting  inactivation  of  C3b  and  C4b  by serine  protease  factor  I (cofactor  activity),
was  shown  to play  a role  in viral  pathogenesis.  However,  the  role  its  individual  complement  regulatory
activities  impart  in pathogenesis,  have  not  yet  been  elucidated.  Here,  we have  generated  monoclonal
antibodies  (mAbs)  that  block  the  VCP  functions  and  utilized  them  to  evaluate  the  relative  contribution  of
complement  regulatory  activities  of  VCP  in  viral  pathogenesis  by  employing  a rabbit  intradermal  model
for  VACV  infection.  Targeting  VCP  by mAbs  that  inhibited  the  decay-accelerating  activity  as  well as cofac-
tor  activity  of VCP  or primarily  the  cofactor  activity  of  VCP,  by  injecting  them  at  the  site  of infection,
signiﬁcantly  reduced  VACV  lesion  size.  This  reduction  however  was  not  pronounced  when  VCP  was  tar-
geted  by  a  mAb  that  inhibited  only  the  decay-accelerating  activity.  Further,  the reduction  in lesion  size
by  mAbs  was  reversed  when  host  complement  was  depleted  by injecting  cobra  venom  factor.  Thus,  our
results  suggest  that targeting  VCP  by  antibodies  reduces  VACV  pathogenicity  and  that  principally  the
cofactor  activity  of VCP  appears  to  contribute  to  the  virulence.. Introduction
The ﬁrst barriers that microorganisms including viruses must
reach for being successful pathogens are imposed by the innate
mmune system of which the complement system constitutes
 major arm [1–4]. The complement system comprises of an
ntricate group of both soluble and cell-associated proteins acti-
ated through three major pathways, the classical, alternative and
ectin pathways. Complement activation results in the genera-
ion of active components, including C3b and C4b, which aid in
he assembly of enzymes called as C3/C5-convertases that facili-
ate downstream cleavage and formation of the membrane attack
omplex (MAC) capable of lysing pathogens. Additionally, the acti-
ation products C3a and C5a show anaphylatoxic and chemotactic
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properties [5] and also play a role in T cell activation [6], and
surface bound complement components derived from C3 interact
with speciﬁc immune receptors, thus acting as a connecting link
with the adaptive immune system [7]. Hence, the complement sys-
tem exerts assault on pathogens directly by lysis and indirectly by
boosting the pathogen-speciﬁc immune responses [8].
Variola  virus, the etiological agent of smallpox, caused large-
scale mortality and morbidity among humans before its successful
eradication. Even though smallpox has been eradicated there are
two major concerns related to poxviruses, one of which is the possi-
bility of usage of variola as a bioterrorism agent and the other being
cross-species related infections, e.g., monkeypox and cowpox virus
infection of humans [9–11], requiring further understanding of the
pathogenesis of this complex group of viruses.
Complement activation either through the alternative pathway
or through the classical pathway plays a pivotal role in the neu-
tralization of poxviruses. Vaccinia virus (VACV), the prototypic
poxvirus, has two  major forms: the extracellular enveloped (EV)
Open access under CC BY license.and the intracellular mature virus (MV). Among these, the EV form
is more resistant to neutralization by antibodies, but this is reversed
in the presence of complement [12]. This is further highlighted by
the observation that both in vitro and in vivo neutralization of the
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Table 1
Kinetic and afﬁnity data for the interactions of monoclonal antibodies with VCP.a
Ligand Analyte kd (1/s)/ka (1/M s) SE (kd/ka) KD (M)  2
mAb 67.5 VCP 0.0164/3.07 × 106 9.52 × 10−5/1.81 × 104 5.35 × 10−9 1.1b
mAb 67.9 VCP 0.0171/2.59 ×106 9.96 ×10−5/1.51 × 104 6.6 × 10−9 1.01b
mAb 67.11 VCP 0.034/7.32 × 105 1.73 × 10−4/7.32 × 105 4.64 × 10−8 0.468b
mAb 67.13 VCP 0.0418/1.8 × 105 5.22 × 10−4/3.94 × 103 2.32 × 10−7 0.218b
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ta ka, association rate constant; kd, dissociation rate constant; KD, equilibrium rate
b Data were calculated by global ﬁtting to a 1:1 Langmuir binding model (BIAeva
V form could be achieved with antibodies targeted against B5R,
n EV form-speciﬁc protein, in the presence of complement [13].
hese studies besides emphasizing the role of antigen speciﬁc anti-
odies also identify the pivotal role complement plays in targeting
nd neutralizing poxviruses.
Viruses  override the complement system by developing various
echanisms to mask themselves against the host’s complement
ssault [14–17]. Poxviruses in particular, have been shown to
ncode mimics of human regulator of complement activation (RCA)
roteins to target complement, besides the additional strategy of
ecruitment of human RCAs [18–21]. Vaccinia and variola viruses,
he two important members of the genus Orthopoxvirus [22,23],
ncode soluble RCA homologs named vaccinia virus comple-
ent control protein (VCP) and smallpox inhibitor of complement
nzymes (SPICE), respectively [24,25]. Both effectively inhibit com-
lement, with SPICE being more human speciﬁc than VCP [25,26].
ther members of the pox family, like cowpox virus, monkey-
ox virus and ectromelia, also encode functional RCA mimics with
arked identity among the homologs, except monkeypox virus
trains, which have been shown to either lack or have a truncated
orm of the homolog [20,27–31].
VCP is entirely formed by four complement control protein
CCP) domains separated by short linkers, which is a character-
stic of the RCA proteins [32–34] and exists either as a secreted
r a cell associated form [24,35]. Functional studies revealed that
t inhibits the complement-mediated neutralization of both the
nfectious forms of VACV i.e., MV  as well as EV [36,37]. Notably,
CP has been shown to be involved in modulating the humoral
nd T cell mediated responses to VACV infection [38]. Detailed
tudies on the mechanism of complement inactivation showed
hat it binds to complement proteins C3b and C4b [39,40] and
nhibits complement by targeting C3-convertases, by supporting
actor I mediated inactivation of C3b and C4b (cofactor activity)
39,41] and by accelerating irreversible dissociation of the clas-
ical pathway C3-convertase (decay-accelerating activity) [39,42].
tructure–function analysis using monoclonal antibodies (mAbs),
himeric proteins and deletion mutagenesis indicated that all the
omains contribute to C3b and C4b binding and functional activities
42–45]. Further, our recent domain swapping study with human
omplement regulators revealed that of the four domains, domain
 imparts decay of the protease subunit from the C3-convertase
nd domains 2 and 3 recruit factor I for imparting proteolytic inac-
ivation of C3b and C4b [46].
The importance of VCP in VACV pathogenesis was addressed
nitially in a study using rabbit and guinea pig intradermal models
here it was shown that VACV devoid of VCP produced compara-
ively smaller lesions than the wild type virus [36]. More recently,
imilar experiments were also performed using mice ear pinnae
odel in complement sufﬁcient and C3−/− mice [38]. Though these
tudies clearly demonstrated the importance of VCP in patho-
enesis, the signiﬁcance of complement inhibition by VCP as a
ontributing factor in the pathogenesis based on the individual
nown functions is still not clear. In the present study, we have
enerated a panel of mAbs against VCP and used them to dissect
he regions on VCP that play a role in the complement regulatorytant; SE; standard error.
n 4.1).
activity.  We  then asked whether VCP could serve as a virulence
determinant by targeting complement and if so, which complement
regulatory activity of VCP plays a predominant role in virulence in
vivo.
2. Materials and methods
2.1.  Virus and proteins
The  vaccinia virus strain Western Reserve (VACV-WR) was  a
kind gift from Dr. Sekhar Chakrabarti (National Institute of Cholera
& Enteric Diseases, Kolkata, India). The virus was  cultured by
infecting African green monkey kidney cells (CV-1) followed by
puriﬁcation on a sucrose gradient. Recombinant VCP (rVCP) and
its truncation mutants (CCP 1–3, CCP 2–4, CCP 1–2, CCP 2–3 and
CCP 3–4) were expressed and puriﬁed as previously described
[42]. The complement proteins C1, C2, C4, C4b and factor I were
purchased from Calbiochem (La Jolla, CA), and complement pro-
teins factor H, C3 [42] and C3b [41] were puriﬁed as described
earlier. Human soluble CR1 (sCR1) was a generous gift from Dr.
Henry Marsh (AVANT Immunotherapeutics, Inc., Needham, MA).
Cobra venom factor (CVF) was  puriﬁed from Naja naja kaouthia
venom as described earlier with minor modiﬁcations [47]. In brief,
the lyophilized venom was  dissolved in 20 mM sodium phosphate
buffer, pH 7.4, loaded onto Source Q column (12 cm × 9.5 cm, GE
Healthcare Bio-Sciences) in the same buffer and eluted with a lin-
ear salt gradient to 1 M NaCl. Fractions containing CVF as judged
by SDS-PAGE were then puriﬁed using Superose 12 column (two
columns linked in a series; GE Healthcare Bio-Sciences) followed
by Mono Q column. SDS-PAGE analysis showed purity of >95%.
Its functionality was veriﬁed by its ability to form the stable C3-
convertase [47].
2.2.  Monoclonal antibodies (mAbs)
The VCP speciﬁc mAbs were generated by immunizing 5–6 week
old BALB/c mice with the rVCP. In brief, mice were immunized
with 20 g of rVCP in Freund’s complete adjuvant, followed by
two boosts 15 days post prime at weekly intervals with the same
dose, but in Freund’s incomplete adjuvant. Following immuniza-
tion, spleen was  removed and the spleen cells were fused in-house
with myeloma cells as per established protocols [48,49]. The clones
from the fusion were screened by ELISA and subcloned to isolate
the individual clones. Antibody isotyping was  performed by an
ELISA-based hybridoma isotyping kit (BD Biosciences, San Diego,
CA, USA). The IgG mAbs were puriﬁed by capryllic acid precipita-
tion method or by Hi-Trap afﬁnity protein G column (GE Healthcare
Bio-Sciences, Sweden). Homogeneity of mAbs was assured by SDS-
PAGE analysis.
2.3.  Rabbit infectionsVACV  pathogenicity studies were performed in rabbits using
skin lesion model [36]. In brief, 104 pfu of VACV-WR strain in sterile
PBS in a total volume of 100 l were injected intradermally with or
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Fig. 1. Surface plasmon resonance analysis of binding of anti-VCP monoclonal antibodies to VCP. Sensogram overlay plots of the binding of anti-VCP mAbs 67.5, 67.9, 67.11
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and  67.13 to VCP. The anti-VCP mAbs were immobilized on the CM-5 sensor chips (B
n  right hand side of each panel) were ﬂown over the chip in PBS containing 0.05
angmuir binding model (A + B ↔ AB; BIAevaluation 4.1).
ithout the mAb  on the shaved backs of two New Zealand White
abbits (age 6–7 months) in duplicate and lesions formed (scabs)
ere measured after every 24 h using calipers. The mean of four
easurements was used for graphical representation of individual
ime point per site. To study the role of complement during infec-
ion, similar experiments were also performed in two  additional
abbits depleted of complement by administering 100 U/kg of cobra
enom factor. All the results were grouped and statistically evalu-
ted by performing Mann–Whitney Rank Sum test (SigmaStat). The
xperimental protocol was approved by the Institute’s Animal Care
nd Use Committee.
.4.  Binding of mAbs to VCP and VCP truncation mutants
The ELISA plates were coated overnight at 4 ◦C with rVCP or
CP mutants (CCP 1–3, CCP 2–4, CCP 1–2, CCP 2–3, CCP 3–4;
00 ng/well), blocked by adding 5% milk and incubated with mAbs
1 g/well) for 1 h at room temperature. Binding was probed by
dding 1:2000 diluted anti-mouse HRP conjugate (Biorad, Her-
ules, CA) and detected with 2,2′-Azino-bis (3-ethylbenzthiazoline)
-sulfonic acid (ABTS) (Roche, Mannheim, Germany) at 414 nm.
.5. Inhibition of factor I cofactor activity of VCP by mAbs
Inhibition of factor I cofactor activity of VCP by mAbs was  deter-
ined as described below. rVCP (0.5 g) was mixed with 3 g of
Ab and incubated for 15 min  at 37 ◦C. Thereafter, 3 g of C3b or
4b and 0.1 g of factor I was added to the reaction mixture and
he volume was adjusted to 20 l using PBS. It was  then further
ncubated at 37 ◦C for 2 h. The reaction was stopped by adding SDS-
AGE sample buffer containing DTT and C3b/C4b cleavages were
nalyzed on a 10% SDS-PAGE gel [40]. AB) using amine-coupling chemistry and various concentrations of VCP (indicated
en 20 to measure binding. The solid black lines represent the best ﬁt data to 1:1
2.6.  Inhibition of classical pathway decay-accelerating activity of
VCP  by mAbs
Inhibition of the classical pathway decay-accelerating activity
of VCP by mAbs was  determined by utilizing a hemolytic assay
[42,50]. Brieﬂy, 10 l of EAC142 (classical pathway C3-convertase;
1 × 109 cells/ml) was mixed with 0.2 M of rVCP and 1 M of mAb
in a total volume of 25 l and incubated for 5 min at 22 ◦C. The
remaining C3-convertase activity was determined by measuring
hemolysis after incubating the reaction mixture for 30 min  at 37 ◦C
with 1:100 diluted guinea pig serum containing 40 mM EDTA.
Hemolysis was  measured at 405 nm.
2.7.  Surface plasmon resonance measurements
The kinetics of binding of the mAbs to VCP was determined
on the SPR-based biosensor BIACORE 2000 (Biacore AB, Uppsala,
Sweden). All the experiments were performed in PBS-T (10 mM
sodium phosphate, 145 mM NaCl, pH 7.4 containing 0.05% Tween
20) at 25 ◦C. About 2600 RUs of each of the mAbs was immobilized
on test ﬂow cells (Fc-2, Fc-3 or Fc-4) of a CM5 chip using amine-
coupling chemistry and non-immobilized ﬂow cell (Fc-1) served as
the control ﬂow cell [40]. Various concentrations of rVCP were then
ﬂown over the chip at 30 l/min for 120 s and dissociation was fol-
lowed for an additional 180 s. The chip was regenerated by injecting
brief pulses of 0.2 M sodium carbonate, pH 9.5. Data obtained for
the control ﬂow cell were subtracted from those obtained for test
ﬂow cell and evaluated using BIAevaluation software version 4.1
using global ﬁtting.2.8.  Measurement of half-life of mAbs in rabbits
The half-life of two of the VCP neutralizing mAbs (NCCS 67.5
and 67.9) in rabbits was assessed by radiolabeling the antibodies
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Fig. 2. Mapping of VCP domains recognized by anti-VCP monoclonal antibodies. Identiﬁcation of VCP domains recognized by the mAb was performed by examining the
binding of the mAbs to various VCP truncation mutants by ELISA. The ﬁlled bars represent binding of the mAbs to the control (BSA), while the empty bars represent binding
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f  VCP to rabbit polyclonal antibody (control). The schematic summary of VCP dom
ith 131I. One hundred microliters of the labeled mAbs at a dose of
00–200 Ci (∼65–100 g) were injected intradermally on backs
f New Zealand White rabbits and imaged using an ELGEMS “Mil-
ennium MPS” gamma  ray camera (GE, USA) at the Department
f Veterinary Medicine and Veterinary Nuclear Medicine Center
Mumbai, India). A maximum of 250 kilocounts was set for acquir-
ng images and a medium energy collimator was used to capture
merging radiations. The images were acquired at various time
oints and analyzed using GENIE acquisition user interface soft-
are (GE, USA). The ﬁrst image acquired immediately after the
njection was considered as zero time point. The data obtained were
ormalized by considering the counts obtained at the zero time
oint as 100%.
.  Results
.1. Anti-VCP monoclonal antibody generation and afﬁnity
easurementsTo  re-examine the VCP domains responsible for complement
odulation and to understand the in vivo relevance of these com-
lement regulatory functions in VACV pathogenesis, we  raised a of mAbs 67.5, 67.9, 67.11 and 67.13, respectively, and panel (E) represent binding
ecognized by the various mAbs is presented in panel (F).
panel of mAbs against VCP by immunizing BALB/c mice followed
by fusion, and cloning and subcloning of the candidate hybrids. The
monoclonal antibodies thus generated largely belonged to IgG1
isotype. Four antibodies, namely NCCS 67.5, NCCS 67.9, NCCS 67.11
and NCCS 67.13, all belonging to IgG1 isotype, were chosen for
further characterization as they differentially inhibited the func-
tional activities of VCP (see below). Of the four, mAb 67.5 uniquely
displayed two distinct light chains, which could be a result of dif-
ference in their glycosylation states [51]. The light chains however
did not show any binding to Con A suggesting that the differ-
ence in their molecular weights was  not a result of difference in
the presence of Con A binding carbohydrates (Supplementary Fig.
1). Although unusual, the clonal origin of an antibody containing
two separate light chains has been reported earlier [52,53]. Thus, it
seems that mAb  67.5 may  belong to such a category.
All the four antibodies bound to VCP in a direct ELISA (data not
shown). Since surface plasmon resonance (SPR) offers more quan-
titative data on biomolecule interactions, we  utilized this method
to measure the afﬁnities of these antibodies. In the SPR setup, the
antibodies were immobilized onto the chip and rVCP was  ﬂowed
over it to measure binding. All the antibodies bound to VCP in a
dose dependent manner (Fig. 1). The equilibrium dissociation con-
stant (KD) of mAbs 67.5 and 67.9 (5.35 × 10−9 M and 6.6 × 10−9 M)
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Fig. 3. Inhibition of factor I cofactor activity of VCP for C3b and C4b by anti-VCP mon-
oclonal antibodies. (A) Inhibition of C3b cofactor activity. C3b (3 g) was  incubated
with  VCP (0.5 g), factor H (1 g; fH; control) or VCP (0.5 g) pre-incubated with
each  of the mAbs (where indicated) and factor I (100 ng) at 37 ◦C for 2 h. The reac-
tions  were stopped by adding SDS-PAGE sample buffer containing DTT and ran on
SDS-PAGE gels. (B) Inhibition of C4b cofactor activity. C4b (3 g) was incubated with
VCP (0.5 g), soluble complement receptor 1 (1 g; sCR1; control), or VCP (0.5 g)
pre-incubated with each of the mAbs (where indicated) and factor I (100 ng) at 37 ◦C
for 2 h. The reactions were stopped by adding SDS-PAGE sample buffer containing
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Fig. 4. Inhibition of classical pathway decay-accelerating activity of VCP by anti-
VCP monoclonal antibodies. The classical pathway (CP) C3-convertase was  formed
on sheep erythrocytes and allowed to decay in the presence of VCP (0.2 M)  or VCP
(0.2 M)  and antibody (1 M).  The remaining C3-convertase activity was  detected
by adding EDTA-sera (a source of C3-C9). The percentage of CP C3-convertase activityTT  and ran on SDS-PAGE gels. The gels were stained with Coomassie blue to visual-
ze inhibition of ′-chain cleavage, which indicates inhibition of C3b or C4b cofactor
ctivity.
as lower compared to those of 67.11 (4.64 × 10−8 M)  and 67.13
2.32 × 10−7 M),  respectively (Table 1). Interestingly, in a dot blot
ssay, these mAbs bound to VCP only under non-reducing condi-
ions (data not shown) indicating that these antibodies recognize
he conformational epitopes on VCP.
.2. Mapping of VCP domains recognized by anti-VCP monoclonal
ntibodies
To identify the VCP domains to which these mAbs bind we
erformed an indirect ELISA using various truncation mutants of
CP (CCP 1–3, CCP 2–4, CCP 1–2, CCP 2–3 and CCP 3–4) that were
xpressed earlier in our laboratory using the Pichia expression sys-
em [42]. These expressed mutants were designed in such a way
hat they started with the ﬁrst Cys of the domain of interest and
nded with the last residue of the inter-domain linker. Thus, this
esign kept the entire linker region at the C-terminal side of each
f the mutants. The mAbs 67.5 and 67.9 reacted with CCP 1–3, CCP
–4, CCP 2–3 and CCP 3–4 mutants (Fig. 2A and B) indicating that
hey recognize either domain 3 or the linker between domains 3
nd 4 (Fig. 2F). The antibodies 67.11 and 67.13 on the other handwas normalized by considering the percentage of lysis in the absence of VCP as 100%.
The dotted line was used as a cut off for determining the inhibition of VCP mediated
decay  of C3-convertase by mAb. NA indicates controls where no antibody was added.
reacted only with truncation mutants CCP 2–4 and CCP 3–4 (Fig. 2C
and D). Since the latter two  antibodies did not show binding to CCP
1–3, CCP 1–2 or CCP 2–3 it indicates that the binding epitopes for
these antibodies lie on CCP domain 4 (Fig. 2F).
3.3. Inhibition of C3b and C4b cofactor activities of VCP by
anti-VCP  monoclonal antibodies
One  of the functions of VCP is to serve as a cofactor for the com-
plement speciﬁc serine protease factor I to mediate the inactivation
of C3b (composed of ′ and  chains) and C4b (composed of ′, 
and  chains), the non-catalytic subunits of C3-convertases, which
are the key enzymes in activation of the complement cascades. This
function results in the cleavage of the ′-chains of C3b and C4b
leading to the generation of their inactivated forms (iC3b or C4c
and C4d) which can no longer participate in the formation of C3-
convertases. As expected, incubation of rVCP or human factor H
(control) with C3b and factor I resulted in cleavage of ′-chain of
C3b (Fig. 3A). Similarly, incubation of rVCP or human sCR1 (con-
trol) with C4b and factor I resulted in cleavage of ′-chain of C4b
(Fig. 3B). When mAbs were analyzed for their ability to inhibit the
C3b cofactor activity of VCP, only 67.5 and 67.9 showed inhibition;
neither 67.11 nor 67.13 could inhibit this activity (Fig. 3A). Essen-
tially similar results were obtained for inhibition of C4b cofactor
activity by the monoclonal antibodies. Only 67.5 and 67.9 showed
inhibition, while 67.11 and 67.13 failed to inhibit the C4b cofactor
activity (Fig. 3B). These data therefore revealed that CCP domain 3
and/or linker between CCPs 3 and 4 of VCP play an essential role in
imparting the cofactor activities.
3.4. Inhibition of decay-accelerating activity of VCP by anti-VCP
monoclonal antibodies
Besides  acting as a cofactor for C3b and C4b inactivation, VCP
is also an efﬁcient decay accelerator of the classical/lectin pathway
C3-convertase C4b,2a. Thus, to examine the effect of mAbs on VCP-
mediated decay of the convertase, we utilized a hemolytic assay. In
this assay, C4b,2a was  formed on antibody sensitized sheep ery-
throcytes using puriﬁed complement components and then the
7440 J.  Bernet et al. / Vaccine 29 (2011) 7435– 7443
Fig. 5. Half-life of anti-VCP mAb  in rabbit. Anti-VCP mAb  67.5 was  labeled with 131I and injected intradermally at two  sites in the back of New Zealand White rabbit (NZW)
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ime period. The data was  normalized by setting 100% equal to the total counts pre
nzyme was allowed to decay in the presence of rVCP or rVCP pre-
ncubated with each of the mAbs. The activity of the remaining
nzyme was assayed by adding EDTA-sera (a source of C3-C9) and
easuring hemolysis. Interestingly, the antibodies that inhibited
he C3b and C4b cofactor activities (67.5 and 67.9) also inhibited
he decay-accelerating activity of VCP, albeit with 67.5 having much
ess effect compared to 67.9. Among the remaining two antibodies
7.11 and 67.13, which bound to CCP 4 domain, only the former
ad moderate inhibitory activity while the latter did not inhibit
he decay activity. The C3-convertase decay inhibition efﬁciency of
he monoclonals followed the order 67.9 ≈ 67.11 > 67.5 with 67.13
aving negligible inhibitory potential (Fig. 4).
.5. Blocking VCP function using monoclonal antibodies reduces
ACV  pathogenicity in rabbits
Since  mAbs differentially inhibited the VCP functions it was
ntriguing to know if blocking VCP function in vivo with these mAbs
ould translate into differences in viral pathogenesis.
For in vivo disabling of VCP using mAbs, a prerequisite is that
hey should be retained at the site of injection until VCP is secreted
y the infected cells. To verify this, we determined their half-life.
he mAbs (67.5 and 67.9) were labeled with 131I, injected intrader-
ally on either ﬂanks of New Zealand White rabbits and imaging
as carried out with a -ray camera. The results showed that the
abeled antibodies were retained at the site of injection even after
2 h. The half-life was found to be 8 h for both the antibodies (Fig. 5;
ata not shown for 67.9).
Next, in order to determine whether disabling of VCP using neu-
ralizing mAb  affects VACV pathogenicity, we used a rabbit skin
esion model. In these experiments, VACV-WR was injected intra-
ermally (104 pfu) either alone or in combination with mAbs and
he lesion size was measured over a period of time. Initially, the two
locking antibodies (67.5 and 67.9) were titrated with VACV-WR to
dentify the optimal concentration required for reduction in lesion
esponse. When varying concentrations of 67.5 (Fig. 6A) or 67.9
data not shown) were mixed with VACV-WR and injected in rab-
its they showed a dose dependent inhibition of lesion formation.ed with an ELGEMS Millennium MPS  gamma ray camera (GE, USA) using a medium
icated time points and the graph represents percentage of counts at the indicated
t 0 time point.
Maximum  decrease in the lesion size was  observed at 25 g mAb
concentration. We  then performed experiments with all the four
mAbs using a ﬁxed concentration (25 g). There was  a signiﬁcant
difference in the lesion size where 67.5 or 67.9 was injected along
with VACV-WR (Fig. 6B). Moderate decrease in the lesion devel-
opment was  also observed where 67.11 was injected, but 67.13
showed a negligible effect on the lesion development. These data
therefore suggested that in vivo inhibition of complement regula-
tory activities of VCP by neutralizing mAbs result in reduction in
VACV pathogenesis.
3.6.  Neutralizing monoclonal antibodies do not reduce VACV
pathogenicity in complement-depleted rabbits
Although the above results suggested that blocking of comple-
ment regulatory activities of VCP by mAbs resulted in neutralization
of virus and in turn its pathogenicity, it still did not provide direct
evidence of a role of host complement. Consequently, we per-
formed similar experiments in two complement-depleted animals.
Complement depletion in rabbits was  achieved by injecting CVF.
A bolus of 100 U/kg administered through the ear vein completely
depleted complement in rabbits in 4 h and the depleted state was
maintained till day 5, after which there was  a gradual restoration
of complement activity (data not shown). Because it took approx-
imately 4 h to completely deplete complement in rabbits, in these
experiments, we injected CVF 6 h prior to the challenge in dupli-
cate with VACV-WR or VACV-WR along with mAb  in the back of
each rabbit. It is clear from our data that intradermal injection of
VACV-WR (104 pfu) with or without mAb  (25 g of each) led to the
formation of more similar sized lesions (Fig. 6C). It could therefore
be suggested that inhibition of VCP-mediated regulation of host
complement by neutralizing antibodies result in neutralization of
VACV in a host complement dependent manner.4. Discussion
VCP is one of the most extensively studied pox viral RCA
homologs [4,54,55]. It is now clear that it possesses the ability to
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Fig. 6. Monoclonal antibody effect in vivo in a rabbit skin lesion VACV-WR challenge
model.  (A) Skin lesions developed after intradermal injection of 104 pfu of VACV-WR
(extreme right lesions marked as C) or 104 pfu of virus mixed with graded concen-
trations  of mAb  67.5 (25 g, 12.5 g, 6.3 g and 3 g, ﬁrst four lesions from left).
The  image was  taken 8 days post infection. (B) Skin lesion size after intradermal
injection  of 104 pfu of VACV-WR alone or in combination with indicated antibod-
ies  (25 g) in rabbits. (C) Skin lesion size after intradermal injection of 104 pfu of
VACV-WR alone or mixed with 25 g of the indicated antibodies in rabbits depleted
of  complement by injecting cobra venom factor 6 h prior to infection. Data points
presented  in panels (B and C) represent mean of four replicates performed in two
rabbits. Statistical comparisons were performed between mAb treated lesions and
u
S
t
r
t
t
b
antreated lesions. *p < 0.01 and **p < 0.001 (Mann–Whitney Rank Sum test, Sigma-
tat).  Differences are also signiﬁcant between 67.13 treated lesions and 67.5/67.11
reated  lesions between days 5 and 11 (p ≤ 0.001).
egulate the complement system in the ﬂuid phase as well as on
he surface of the infected cells by binding to heparan sulfate pro-
eoglycans [56] and the viral protein A56 [35]. Further, it has also
een established that its deletion causes attenuation of VACV lesion
nd increase in speciﬁc inﬂammatory responses in mice [36,38]. (2011) 7435– 7443 7441
However,  the in vivo role of its complement interacting domains
and importance of its various inhibitory activities with relevance to
in vivo pathogenesis is still not understood. In the present study, we
have raised neutralizing mAbs against VCP, mapped the domains
they recognize and utilized them to address the in vivo relevance
of different functional activities of VCP in VACV pathogenesis.
Prior to this study, mAbs against VCP have been generated by
Isaacs et al. [45] and Liszewski et al. [57]. The former study by
Isaacs et al. [45] showed that mAbs directed against CCP domains
2 and 4 inhibit VCPs interaction with its target proteins C3b and
C4b and thereby its activity. And later Liszewski et al. [57] demon-
strated that mAb  that recognizes the linker between CCP domains
1 and 2 inhibit the cofactor as well as decay-accelerating activ-
ity of VCP. Although these studies established the importance of
CCP domains 2 and 4 and the linker between domains 1 and 2 in
VCPs target recognition and functional activities, no attempts were
made in these studies to utilize the antibodies to dissect the in vivo
importance of complement regulatory activities of VCP in VACV
virulence.
In the present study, we have characterized four mAbs of which
two (67.5 and 67.9) recognized domain 3 or the linker between
domains 3 and 4, and the other two (67.11 and 67.13) recognized
domain 4. Of these four antibodies, 67.5, 67.9 and 67.11 inhibited
the complement regulatory activities of VCP (Figs. 3 and 4) sug-
gesting that domains 3 and 4 are critical for the VCP function. This
however is not surprising as domain mapping employing chimeric
mutants, truncation mutants and mAbs indicated that all the four
domains of VCP are important for its interaction with C3b and C4b
[42–45]. In addition, we now also know that CCP domains 2 and 3
provide a docking surface for factor I and thus are critical for the
cofactor activity, and CCP domain 1 is essential for displacement of
C2a from the C3-convertase C4b,2a (decay activity) [46]. In light of
these data on domain requirements in VCP for its functional activ-
ities, it is likely that the mAbs 67.5 and 67.9 exert their effect by
inhibiting the interaction of VCP with C3b/C4b and/or factor I and
mAb 67.11 exercises its effect by inhibiting the interaction of VCP
with C3b/C4b.
The  mAbs characterized here displayed differential effect on the
cofactor and decay activities of VCP. The mAb 67.5 primarily inhib-
ited the cofactor activity, 67.9 inhibited both the cofactor activity
and the decay-accelerating activity, 67.11 inhibited only decay-
accelerating activity and 67.13 did not inhibit any of the activities
(Figs. 3 and 4). Hence, these were suitable to gain insight into
the role of these activities of VCP in VACV pathogenesis. Here we
employed the rabbit intradermal model to study the effect of these
neutralizing antibodies on VACV pathogenesis [36]. Injection of
mAbs 67.5 and 67.9 along with VACV showed signiﬁcant reduction
in the lesion size when compared to the lesions formed by VACV
alone or VACV injected with the control antibody (67.13) (Fig. 6A
and B), indicating that like deletion of VCP from VACV [38,46], dis-
abling of VCP functions also leads to attenuation of VACV lesions.
Interestingly, mAb  67.11 that inhibited only the decay-accelerating
activity of VCP had no signiﬁcant effect on the lesion formation sug-
gesting thereby that the cofactor and not the decay-accelerating
activity plays a major role in contributing to virulence (Fig. 6B).
Nonetheless, there are a few caveats. The afﬁnity of 67.11 for VCP
is about 10-fold less compared to 67.9 (Fig. 1 and Table 1) and there-
fore it is also likely that the observed difference in lesion formation
is due to the variation in the afﬁnities of these two antibodies for
VCP. Interpretation of the viral pathogenicity data employing mAb
67.11 is further complicated by the fact that even in the in vitro
DAA assay, its effect was  a relatively modest one. A closer look at
the data however show that mAb  67.5, despite having compara-
tively poor DAA inhibitory activity than 67.9, is equally efﬁcient
in inhibiting the lesion formation. Moreover, both these antibod-
ies display similar afﬁnities for VCP (Fig. 1 and Table 1). Thus, it is
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ikely that cofactor activity is a major contributor to VCP-mediated
nhancement of VACV pathogenesis.
Monkeypox virus strains like Central African (Congo basin)
train encodes a complement regulator (ORF D14L), while the West
frican strain lacks this protein [28]. A comparison of the West
frican strain versus the Congo basin strain shows the latter to be
ore virulent than the former [28] suggesting that complement
vasion may  play a role in poxvirus pathogenesis. Intriguingly,
he Congo basin strain encodes a protein (MOPICE) that con-
ains only cofactor activity and lack the decay activity [21]. Thus,
hese observations also provide support to our proposal that the
ofactor activity of VCP could play a major role in the poxvirus
athogenesis.
Although smallpox has been eradicated from the globe, the
ecent upsurge in terrorism has increased the concern of usage
f variola virus as a biological weapon and has resulted in devel-
pment of new generation vaccines [11]. The important question
herefore is should VCP be present in the new generation vaccine
ectors? We  show here that disabling of complement regulatory
ctivities of VCP by neutralizing mAbs result in reduction of VACV
esion size in rabbits and this reduction is dependent on the pres-
nce of host complement (Fig. 6). Although our study does not
eﬁne the mechanism responsible for this, clearly there are two
ossibilities: (i) the lack of VCP-mediated host complement regula-
ion could result in complement-mediated neutralization of VACV
n the presence of antibodies that are produced against VACV during
he infection and (ii) the lack of VCP-mediated complement regula-
ion could enhance the protective immune response against VACV.
oth these probabilities have been established by earlier studies. In
upport of the ﬁrst possibility, in vitro studies have shown that com-
lement has the ability to neutralize both MV  [36,37] and EV [37]
n the presence of anti-VACV antibodies. And an in vivo study has
emonstrated complement to be protective against poxvirus infec-
ion [58]. Similarly, in support of the second alternative, a recent
tudy has elegantly shown that infection of VCP-null VACV in mice
esults in enhanced T cells at the site of infection, enhanced neu-
ralizing antibody responses and reduced viral titers [38]. Thus, our
tudy along with these studies suggests that deletion of VCP from
he new generation vaccine vectors would result in more safe and
ffective vaccine vectors against smallpox.
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